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ABSTRACT 
Background: There has been increasing evidence that chronic low-grade inflammation is associated with 
mood disorders. However, the findings have been inconsistent because of heterogeneity across studies 
and methodological limitations. Our aim is to prospectively evaluate the bi-directional associations 
between inflammatory markers including Interleukin (IL)-6, Tumor Necrosis Factor (TNF)-α and high 
sensitivity C-reactive protein (hsCRP) with mood disorders.  
Methods: The sample consisted of 3,118 participants (53.7% women; mean age: 51.0, s.d. 8.8 years), 
randomly selected from the general population, who underwent comprehensive somatic and psychiatric 
evaluations at baseline and follow-up (mean follow-up duration = 5.5 years, s.d. 0.6). Current and 
remitted mood disorders including bipolar and major depressive disorders (MDD) and its subtypes 
(atypical, melancholic, combined atypical and melancholic, and unspecified) were based on semi-
structured diagnostic interviews. Inflammatory biomarkers were analyzed in fasting blood samples. 
Associations were tested by multiple linear and logistic regression models. 
Results: Current combined MDD (β=0.29, 95% CI: 0.03-0.55) and current atypical MDD (β=0.32, 95% CI: 
0.10-0.55) at baseline were associated with increased levels of hsCRP at follow-up. There was little 
evidence for inflammation markers at baseline predicting mood disorders at follow-up. 
Conclusions: The prospective unidirectional association between current MDD subtype with atypical 
features and hsCRP levels at follow-up suggests that inflammation may be a consequence of this 
condition. The role of inflammation, particularly hsCRP that is critically involved in cardiovascular 
diseases, warrants further study. Future studies may examine whether treatment of depression may 
lead to a decrease in inflammation and consequently a decrease in cardiovascular risk. 
 
Key-words: mood disorders; atypical depression; pro-inflammatory cytokines; C-Reactive protein; 
prospective study; cardiovascular risk factors.  
3 
 
INTRODUCTION 
Mood disorders and cardiovascular diseases (CVD) are among the highest sources of morbidity and 
premature mortality worldwide (GBD 2015 DALYs and HALE Collaborators 2016) . Moreover, their high 
comorbidity (Van der Kooy et al. 2007, Glaus et al. 2013) is associated with even greater disability 
adjusted life years than either disorder alone (Charlson et al. 2013). An increasingly recognized 
mechanism to explain comorbidity of CVD with mood disorders is common underlying low-grade 
inflammation. Specifically, there is a consistent association between circulating levels of pro-
inflammatory cytokines, such as Interleukin (IL)-1β, IL-6 and Tumor Necrosis Factor (TNF)-α, and the 
acute phase reactant C-Reactive Protein (CRP) with both mood disorders(Howren et al. 2009, Dowlati et 
al. 2010, Modabbernia et al. 2013, Glaus et al. 2014)  and CVD (Baune et al. 2012). Alternatively, such 
inflammatory processes could also provoke mood disorders or CVD through, for instance, stress- 
induced perturbation of the Hypothalamic-Pituitary-Adrenal (HPA) axis (Rosmond et al. 2000, Watson 
2006). Conversely, mood disorders could induce inflammation through similar mechanisms (Rosenblat 
et al. 2014). 
Although the bulk of prospective research on inflammatory markers and CVD has focused on major 
depression, comparably few studies have examined the extent to which associations extend to other 
mood disorders, such as bipolar disorder (BPD)(Van der Kooy et al. 2007, Modabbernia et al. 2013). In a 
recent meta-analysis of 25 cross-sectional studies and 2 longitudinal analyses (changes in CRP levels 
before and after treatment for mania and depression), BPD disorder was associated with increased 
levels of CRP (Fernandes et al. 2016). In another meta-analysis of 30 cross-sectional studies, BPD 
disorder was associated with increased levels of IL-6 and TNF-α (Modabbernia et al. 2013). 
Moreover, few longitudinal studies have examined depressive subtypes (Rothermundt et al. 2001, 
Kaestner et al. 2005, Yoon et al. 2012, Lamers et al. 2013, Glaus et al. 2014, Hickman et al. 2014, Rudolf 
et al. 2014) that have been shown to be highly heterogeneous (Schmidt et al. 2011, Lopresti et al. 2014) 
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and even fewer studies have considered the well-established comorbidity among mental disorders 
(Stewart et al. 2009, Kivimaki et al. 2014) or current versus past disorders (Whooley et al. 2008).  
 
With respect to directionality, longitudinal studies of the links between mood disorders and 
inflammation have predominantly been performed in patients with a major depressive disorder (MDD) 
(Valkanova et al. 2013, Chocano-Bedoya et al. 2014, Kivimaki et al. 2014, Tully et al. 2015). Recent meta-
analyses (Valkanova et al. 2013) and more recent studies (Chocano-Bedoya et al. 2014, Tully et al. 2015) 
have shown  that these associations between inflammatory factors and mood disorders may be partially 
attributable to potential confounders, including body mass index (BMI) and smoking. Similar findings 
regarding mediation by BMI and behavioral cardiovascular risk factors (CVRFs) have also emerged from 
prospective studies of inflammation as a potential consequence of mood disorders (Matthews et al. 
2007, Gimeno et al. 2009, Stewart et al. 2009, Duivis et al. 2011). However, to date, the few studies that 
have examined the bi-directional associations simultaneously have yielded conflicting results (Gimeno et 
al. 2009, Stewart et al. 2009, Matthews et al. 2010, Duivis et al. 2011). The aggregate findings from 
these studies highlight the importance of incorporating CVRFs including diabetes (Marques-Vidal et al. 
2012a), overweight (Marques-Vidal et al. 2012b, Kiecolt-Glaser et al. 2015), smoking (Yanbaeva et al. 
2007), chronic alcohol consumption (Achur et al. 2010) and physical inactivity (Hamer 2007, Kiecolt-
Glaser et al. 2015) along with depression and anxiety (e.g. (Agosti et al. 2006, Mezuk et al. 2008, Chaiton 
et al. 2009, Anthenelli 2010, Luppino et al. 2010, Glaus et al. 2013, Lasserre et al. 2014, Kiecolt-Glaser et 
al. 2015)), when examining the association with inflammation.  
 
Our previous cross-sectional findings from a large community cohort revealed that there were 
significantly elevated levels of high sensitivity CRP (hsCRP) among those with the atypical subtype of 
depression and bipolar disorders, but these associations were explained by concurrent CVRFs, such as 
BMI, diabetes and hypertension (Glaus et al. 2014). In the present study, we extend these earlier cross-
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sectional analyses from our large community-based cohort in Lausanne, Switzerland, to examine the 
directionality, specificity, timing, and potential causal versus common etiologic mechanisms for 
associations between mood disorders and markers of a chronic low-grade inflammation by addressing 
the following aims: (1) to evaluate the 5-year prospective associations between mood disorders 
including their subtypes, and changes in circulating levels of specific inflammatory markers (IL-6, TNF-α, 
hsCRP) to determine the specificity of the associations; (2) to assess the directionality of links between 
inflammatory markers and mood disorders; (3) to examine whether the markers comprise state versus 
trait indices by comparing remitted versus current disorders, as well as incident cases; and (4) to 
examine the role of health behaviors, CVRFs, and treatment factors that may influence this association. 
Based on our previous cross-sectional study (Glaus et al. 2014), we hypothesized to find an association 
between the atypical subtype of depression and increased levels of inflammatory markers, whereas 
other subtypes of major depressive disorders were not expected to be associated with increased 
inflammation. 
 
 
METHODS AND MATERIALS 
Study sample 
We drew the data for the present investigation from CoLaus|PsyCoLaus (Firmann et al. 2008, Preisig et 
al. 2009), a cohort study designed to prospectively assess the associations between mental disorders 
and CVD or CVRFs in the community. The sample was randomly selected from the civil register of the 
city of Lausanne (Switzerland) in 2003. Sixty-seven percent of participants between 35 and 66 years-of 
age (n=5,535), who underwent the physical exam between 2003 and 2006, also accepted the psychiatric 
evaluation, resulting in a sample of 3,719 individuals at baseline (Preisig et al. 2009) (see Figure 1, flow 
chart). The mean interval between the physical and psychiatric evaluations at baseline was 1.33 years 
(s.d. 0.51). Five years later, 3,191 participated in the physical exam (85.8% participation). Among them, 
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61 participants were excluded due to missing information on inflammatory markers both at baseline and 
follow-up, 9 subjects were excluded due to missing information on mental disorders and 3 subjects were 
excluded due to missing information on CVRFs. The final sample used to examine associations between 
mood disorders at baseline and inflammation at follow-up consisted of 3,118 participants in total (53.7% 
women; mean age: 51.0, s.d. 8.8 years): 2,796 participants were analyzed for cytokines levels, and 2,896 
for hsCRP levels. The mean follow-up duration for the physical examination was 5.5 years (s.d. 0.6 
years). The mean follow-up duration for the mental health assessment was 5.5 years (s.d. 0.8). The 
number of participants with data on the psychiatric evaluation at follow-up was 2,840. Among them, 
258 participants were excluded due to missing information on inflammatory markers and 2 participants 
due to missing information on CVRFs. The resulting number of participants used to determine the 
association between inflammation at baseline and mental disorders at follow-up was 2,580. The 
Institutional Ethics’ Committee of the University of Lausanne approved the CoLaus and the PsyCoLaus 
study. All participants provided written informed consent for the study protocol. 
 
Measurements 
Mood disorders and comorbid disorders 
Mental disorders at baseline and follow-up were assessed using the French version (Leboyer et al. 1995) 
of the semi-structured Diagnostic Interview for Genetic Studies (DIGS), which was developed and 
validated by the National Institute of Mental Health (Nurnberger et al. 1994). The French version of this 
instrument revealed adequate inter-rater and test-retest reliability for major mood (Preisig et al. 1999) 
and substance use disorders (Berney et al. 2002). The DIGS was completed with sections on generalized 
anxiety and phobia disorders using questions from the Schedule for Affective Disorders and 
Schizophrenia-Lifetime and Anxiety disorder version (SADS-LA (Endicott et al. 1978)), which also 
revealed satisfactory test-retest reliability (Leboyer et al. 1991, Rougemont-Buecking et al. 2008). 
Interviewers were required to be masters-level psychologists and were trained over a two-month 
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period. In order to provide ongoing supervision throughout the study, each interview and diagnostic 
assignment was reviewed by an experienced senior psychologist. Diagnoses were assigned according to 
the DSM-IV. Following Angst et al. (Angst et al. 2006), MDD was subtyped into: 1) MDD with at least one 
atypical and one melancholic episode or MDD with atypical and melancholic features simultaneously 
(combined type); 2) MDD with at least one atypical (but no melancholic) episode; 3) MDD with at least 
one melancholic (but no atypical) episode; and 4) MDD with neither atypical nor melancholic episodes 
(unspecified type). We defined MDD as current if it was present at the time of the physical evaluation.  
 
Inflammatory markers 
HsCRP was assessed during baseline and follow-up physical evaluations using immunoassay and latex HS 
(IMMULITE 1000-High, Diagnostic Products Corporation, LA, CA, USA), with maximum intra- and 
interbatch coefficients of variation of 1.3% and 4.6%, respectively (Firmann et al. 2008). Subjects with a 
hsCRP level higher than 10 mg/l were excluded as such an elevation is likely to be attributable to acute 
infection (Pearson et al. 2003). For the baseline and follow-up cytokine measurements, serum was 
preferred to plasma, as it has been shown that different anticoagulants may differentially affect 
absolute cytokine levels (Skeppholm et al. 2008). Serum samples were stored at -80°C before 
assessment and sent on dry ice to the laboratory. As previously described, cytokine levels were 
measured using a multiplexed particle-based flow cytometric cytokine assay (Marques-Vidal et al. 2011). 
Lower detection limits (LOD) for IL-6 and TNF-α were 0.2 pg/ml. Good agreement between signal and 
cytokine was found within the assay range (R2 ≥ 0.99). 
 
Covariates 
Data were collected on age, race (Caucasian versus non-Caucasian), marital status (living alone versus 
living with someone) and health-related behaviors at baseline including smoking (never, former, 
current) and physical inactivity (no or low versus at least 20 minutes twice a week). Information on 
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socio-economic status (SES) and on psychotropic drug treatment was derived from the DIGS. The level of 
SES was assessed using the Hollingshead scale (Hollingshead 1975). The section on psychotropic drug 
treatment covered all types of antidepressants, mood stabilizers (lithium and anti-epileptics) and 
antipsychotics. Moreover, information on aspirin and statin use was collected during the baseline 
physical evaluation (never versus occasional versus regular use). The following biological variables were 
measured during the baseline physical evaluation: BMI (weight in kilograms divided by height in meters 
squared), diabetes (fasting blood glucose ≥ 7 mmol/l or treatment for diabetes), dyslipidemia (HDL-
cholesterol < 1 mmol/l, or LDL-cholesterol ≥ 4.1 mmol/l, or triglycerides ≥ 2.2 mmol/l, or treatment with 
a lipid-lowering drug), hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 
90 mmHg, or treatment for hypertension). 
 
Statistical analysis 
Statistical analyses were conducted using the Statistical Analysis System (SAS Institute Inc., Cary, NC, 
USA), version 9.3 for Windows. Age was standardized. Descriptive data for demographic characteristics, 
comorbid disorders, medication, health-related behaviors, physical risk factors for CVD and 
inflammatory marker levels were derived by lifetime mood disorders and Chi-square and Kruskal-Wallis 
tests were used to determine the difference between mood disorders. P-values were not adjusted for 
multiple testing because the hypothesized associations between mood disorders and inflammatory 
markers were specified a priori. 
Associations between current and remitted mood disorders at baseline and changes in inflammatory 
markers at follow-up were determined using multiple linear regression models. Box-Cox transformation 
was applied to the response variable whenever a deviation from fundamental assumptions was 
observed. Values below the LOD of 0.2 [pg/ml] (i.e., 5% of values for IL-6, 0.5% of values for TNF-α) were 
considered as censored observations. IL-6 and TNF-α were analyzed with the qualitative and limited 
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dependent variable model (QLIM) with the threshold of -1.65 [log (pg/ml)] as the meaningful lower 
bound of observed values. 
A multiple linear regression model was performed on naturally log-transformed and standardized 
observed values. Three models of increasing complexity were computed. Model 1 included one single 
mood disorder (current and remitted) at a time as the independent variable, adjusted for the 
corresponding inflammatory marker at baseline. Model 2 included current and remitted mood disorders 
simultaneously in order to determine the associations of specific mood disorder with inflammatory 
markers at follow-up, adjusting for the length of follow-up, sociodemographic characteristics (sex, age, 
SES, race and marital status), comorbid disorders (anxiety and substance use disorders), health-related 
behaviors and physical risk factors for CVD at baseline and the covariate of Model 1. In case of 
significant associations, additional models also adjusted for the occurrence of new episodes in order to 
test whether the associations persist after the offset of depressive episodes. Similar models adjusted for 
the occurrence of new physical risk factors for CVD during the follow-up in order to test whether the 
prospective associations between mood disorders and inflammation marker levels were independent of 
the occurrence of these new risk factors. 
Associations between inflammatory markers at baseline and a history of mood disorders during the 
follow-up period were determined using logistic regression models. Two models were computed. Model 
1 included all inflammatory markers simultaneously, adjusting for the corresponding history of mood 
disorder at baseline. Model 2 was further adjusted for the length of follow-up, sociodemographic 
characteristics, health-related behaviors and physical risk factors for CVD.  
 
RESULTS 
Sample characteristics 
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The description of the cohort of 3,118 participants used for the assessment of the prospective 
associations between mood disorders at baseline and the concentrations of inflammatory markers at 
follow-up is presented in Table 1. The groups (bipolar disorder, MDD subtypes and no history of mood 
disorders) differed with respect to sex, age, marital status, comorbid disorders, medication, current 
smoking status, BMI and hypertension. Moreover, the groups also differed with respect to hsCRP levels 
at baseline and at follow-up.  
Associations between mood disorders at baseline and inflammatory markers at follow-up 
Associations between current and remitted mood disorders at baseline and changes in levels of 
inflammatory markers are presented in Table 2 and 3. When models were only adjusted for the 
corresponding inflammatory marker at baseline (Table 2), current MDD, as well as the current combined 
and atypical MDD subtypes were associated with increased hsCRP levels. Moreover, current combined 
MDD was associated with decreased IL-6 levels. No significant associations were found for remitted 
mood disorders with inflammatory markers. When the model was further adjusted for potential 
confounders, MDD was no longer significantly associated with hsCRP levels (β=0.09, 95%CI -0.02-0.21). 
In contrast, current combined MDD was associated with increased hsCRP levels and decreased IL-6 
levels and current atypical MDD was associated with increased hsCRP levels at follow-up (Table 3). 
Moreover, remitted melancholic MDD was associated with decreased IL-6 levels at follow-up in the fully 
adjusted model (Table 3).Additional analyses revealed that the occurrence of new mood episodes during 
the follow-up did not affect the size of the associations between current mood disorders at baseline and 
the hsCRP at follow-up. Similarly, the occurrence of incident physical risk factors for CVD did not account 
for the associations between current combined MDD or current atypical MDD at baseline and the hsCRP 
at follow-up. 
Since an association was found between the atypical MDD subtype and increased hsCRP levels at follow-
up, we also looked at the correlation between the age of onset of atypical MDD and inflammatory 
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markers. Interestingly, later atypical MDD onset was correlated with increased hsCRP levels (Pearson 
correlation = 0.16, p-value = 0.0214). 
Associations between inflammatory markers at baseline and mood disorders at follow-up 
Regarding the associations between inflammatory markers at baseline and mood disorders at follow-up, 
higher levels of TNF-α were associated with a decreased risk of MDD and of the MDD atypical and 
unspecified subtypes after controlling for a history of depression at baseline (Table 4). After controlling 
for all the covariates (Model 2), higher levels of TNF-α were still associated with a decreased risk of MDD 
and of the MDD unspecified subtype, but not with the MDD atypical subtype. Moreover, levels of IL-6 
and hsCRP at baseline were not associated with any mood disorders at follow-up. 
We also tested the associations between inflammatory markers at baseline and incident cases of mood 
disorders excluding subjects that already had a lifetime history of this disorder at baseline. However, no 
significant associations were found (results not shown). 
 
DISCUSSION 
The present study prospectively assessed the bi-directional 5-year associations between mood disorder 
and its subtypes with several inflammatory markers with serial adjustments for sociodemographic, 
comorbid mental disorders, medication use, health behaviors, and CVRFs, in a large community sample 
of adults. Our results showed differential associations depending on temporal ordering, current versus 
remitted status of the mood disorder, the specific type of mood disorder and different indices of 
inflammation. The major finding is that there is an association between the current atypical subtype of 
MDD at baseline with increased levels of hsCRP at follow up, whereas inflammatory levels at baseline 
were not associated with subsequent atypical MDD at follow-up. This unidirectional association 
indicates that this disorder may be causally related to increased inflammation, rather than inflammation 
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comprising a vulnerability factor for mood disorders.  Future studies with more closely timed follow-up 
assessments may inform potential mechanisms for elevation of hsCRP among those with this condition. 
Our finding of unidirectional associations between MDD and elevated hsCRP levels appear to be specific 
to the atypical subtype of MDD, which is characterized by somatic symptoms including sleep, energy and 
eating behavior (Rothermundt et al. 2001, Kaestner et al. 2005, Stewart et al. 2009, Duivis et al. 2011, 
Copeland et al. 2012, Lamers et al. 2013, Glaus et al. 2014, Hickman et al. 2014, Rudolf et al. 2014, 
Schmidt et al. 2014). This finding suggests that the atypical MDD is associated with more detectable 
immune dysfunction. This could be a primary characteristic of this disorder or reflect other indirect 
factors, such as greater disturbance of circadian systems, HPA systems or other relevant immune 
modulators. A similar link between cumulative depressive episodes and CRP at follow-up in a 
prospective study of a community sample of youth would confirm this explanation and further imply 
that the associations observed herein may be present across the life span (Copeland et al. 2012).The 
specificity of the findings with respect to the atypical subtype rather than BPD (Modabbernia et al. 
2013), as shown in previous studies of adults and youth, further suggests that the somatic 
manifestations of depression may be etiologically related to inflammation. Although our sample of 
subjects with a lifetime history of BPD only included 55 subjects, which does not allow us to draw 
definitive conclusions, our results do not provide any clues for increased levels of inflammation in these 
subjects, which could also be attributable to the fact that except for two all these bipolar subjects were 
in remission. Interestingly, a previous case-control study (Cunha et al. 2008) evaluating BPD patients in 
different phases of the illness found increased hsCRP levels in patients with a current manic episode 
compared to depressed, euthymic patients and healthy controls suggesting a state-dependent effect of 
manic episodes. Moreover, recent studies also found that mania and to a lesser extent depression in 
BPD patients are associated with pro-inflammatory cytokines (Muneer 2016). To our knowledge, no 
studies have examined depressive subtypes in BPD compared to MDD patients and healthy controls. 
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Future prospective studies should further investigate the different state-related associations between 
mood disorder subtypes and inflammation. 
The lack of association between inflammatory markers at baseline and subsequent mood disorders at 
follow-up suggests that inflammation may not be a risk factor for the onset of mood disorders. This 
result extends the findings of two previous longitudinal studies, which found that depression predicted 
higher inflammation, whereas inflammation did not predict depression (Stewart et al. 2009, Duivis et al. 
2011). However, our results are in contradiction with two studies that showed inflammatory levels to 
predict depressive symptoms, but depressive symptoms did not predict changes in inflammation levels 
(Gimeno et al. 2009, Matthews et al. 2010). Moreover, our findings are also in contradiction with a 
previous meta-analysis (Valkanova et al. 2013) and another prospective study which found increased 
CRP levels to be associated with increased depressive symptoms (Tully et al. 2015). These discrepancies 
could be due to methodological differences. Indeed, depressive symptoms and not depression diagnosis 
were assessed and no depressive subtypes were analyzed. 
 
The restriction of our findings to the hsCRP, which has been shown to lead to broader manifestations of 
the metabolic syndrome, rather than the pro-inflammatory cytokines, particularly among those with 
current disorders rather than symptoms alone (Gimeno et al. 2009, Matthews et al. 2010), further 
suggests that the physical symptoms of these conditions may induce a stress-like physiologic reaction in 
affected individuals. Accordingly, depression may contribute to a chronic low-grade inflammatory state, 
which, in turn, might lead to a vascular pathology and ultimately to atherosclerotic vascular disease 
(Wagner et al. 2015). Several potential pathophysiological mechanisms have been suggested to underlie 
the association between depression and higher inflammation, including HPA axis activation and 
oxidative stress (Rosenblat et al. 2014). However, future longitudinal studies are needed to confirm 
these potential mechanisms. 
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Our results should be interpreted in the context of several limitations. First, there was an interval of 
almost one year between the physical and the psychiatric evaluations. Although the timing of depressive 
episodes was elicited in our diagnostic interviews, we cannot exclude misclassification regarding the 
"current" status of disorders at the time of the physical evaluation. Second, inflammatory markers were 
only assessed once at baseline and 5.5 years later at follow-up, which only partially reflected the 
dynamic temporal relationship between mood disorders and inflammatory markers over time. However, 
despite this limitation our findings still support longstanding increase of inflammation in subjects with 
specific subtypes of mood disorders. Third, low-grade inflammation was measured by hsCRP and 2 pro-
inflammatory cytokine levels, but other pro-inflammatory (i.e. IL-1β, IL-2, IFN-γ) or anti-inflammatory 
(i.e. IL-4, IL-8, IL-10) cytokines and other potential biomarkers of inflammation, such as cortisol, 
leucocytes and thrombocytes were not included. Nevertheless, this is one of the largest prospective 
studies of a community sample, with the hitherto longest follow-up period. It is the first study to 
investigate the full range of mood disorder subtypes. Forth, with only 55 subjects with a lifetime history 
of BPD at baseline and only 13 subjects who had developed this disorder during the follow-up we did 
not have adequate power to test the longitudinal associations between this disorder and inflammatory 
markers. 
These prospective data from a large community sample show that unidirectional association between 
current MDD subtypes with atypical features and increased hsCRP levels at a more than 5-year follow-up 
may be a consequence of this condition. Further prospective studies with repeated assessments of 
inflammatory markers earlier in the development of mood disorders are required to examine whether 
successful treatment of depression could lead to a decrease in inflammation and consequently 
cardiovascular risk. 
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TABLE 1: Sociodemographic, Medication, Health-Related Behaviors, Physical Risk Factors for Cardiovascular Disorders and Inflammatory markers by 
lifetime mood disorders at baseline (n=3118) 
 
Bipolar disorder 
 
MDD 
 Major depressive disorder subtypes  No Mood 
Disorders 
 
p-value a    
Combined MDD  Atypical MDD  
Melancholic 
MDD  
Unspecified 
MDD   
 n = 55  n = 1367  n = 171  n = 206  n = 362  n = 628  n = 1696  
 Current n = 2  Current n = 213  Current n = 36  Current n = 47  Current n = 49  Current n = 81     
 Remitted n = 53  Remitted n = 1154  Remitted n = 135  Remitted n = 159  Remitted n = 313  Remitted n = 547     
Sociodemographics                       Length of follow-up, mean (SD) 5.62 (0.71)  5.51 (0.59)  5.46 (0.61)  5.51 (0.55)  5.53 (0.57)  5.51 (0.61)  5.54 (0.63)  0.568
b 
Sex, n (%)                       Female 26 (47.27)  899 (65.76)  123 (71.93)  148 (71.84)  245 (67.68)  383 (60.99)  748 (44.10)  <.0001 Male 29 (52.73)  468 (34.24)  48 (28.07)  58 (28.16)  117 (32.32)  245 (39.01)  948 (55.90)  Age, mean (SD) 51.15 (8.43)  50.33 (8.71)  50.64 (8.84)  49.56 (8.68)  50.60 (8.69)  50.35 (8.70)  51.53 (8.87)  0.007
b 
Socio-economic status, mean (SD) 3.33 (1.29)  3.42 (1.26)  3.31 (1.24)  3.34 (1.21)  3.39 (1.34)  3.50 (1.23)  3.42 (1.28)  0.381
b 
Ethnicity, n (%)                       Caucasian 55 (100.00)  1251 (91.51)  160 (93.57)  191 (92.72)  331 (91.44)  569 (90.61)  1575 (92.87)  0.119 Other 0 (0.00)  116 (8.49)  11 (6.43)  15 (7.28)  31 (8.56)  59 (9.39)  121 (7.13)  Marital status, n (%)                       Living alone 25 (45.45)  547 (40.01)  65 (38.01)  93 (45.15)  153 (42.27)  236 (37.58)  429 (25.29)  <.0001 Living in couple 30 (54.55)  820 (59.99)  106 (61.99)  113 (54.85)  209 (57.73)  392 (62.42)  1267 (74.71)  Comorbid disorders, n (%)                       Anxiety disorders 22 (40.00)  340 (24.87)  56 (32.75)  51 (24.76)  94 (25.97)  139 (22.13)  204 (12.03)  <.0001 Substance use disorders 13 (23.64)  218 (15.95)  31 (18.13)  22 (10.68)  60 (16.57)  105 (16.72)  240 (14.15)  0.060 Medication, n (%)                       Antidipressants 28 (50.91)  522 (38.19)  86 (50.29)  91 (44.17)  176 (48.62)  169 (26.91)  90 (5.31)  <.0001 Mood stabilizers 12 (21.82)  8 (0.59)  1 (0.58)  1 (0.49)  5 (1.38)  1 (0.16)  2 (0.12)  <.0001 Antipsychotics 10 (18.18)  32 (2.34)  8 (4.68)  4 (1.94)  9 (2.49)  11 (1.75)  9 (0.53)  <.0001 Aspirin 10 (18.18)  121 (8.85)  17 (9.94)  24 (11.65)  33 (9.12)  47 (7.48)  130 (7.67)  0.030 Statins 6 (10.91)  93 (6.80)  12 (7.02)  14 (6.80)  23 (6.35)  44 (7.01)  132 (7.78)  0.819 Health-related behaviors, n (%)                       Former smoking 21 (38.18)  441 (32.26)  49 (28.65)  64 (31.07)  112 (30.94)  216 (34.39)  569 (33.55)  0.557 Current smoking 21 (38.18)  417 (30.50)  62 (36.26)  54 (26.21)  102 (28.18)  199 (31.69)  423 (24.94)  0.001 Physical inactivity 21 (38.18)  600 (43.89)  78 (45.61)  97 (47.09)  148 (40.88)  277 (44.11)  737 (43.46)  0.681 Biological risk factors                       Body mass index, mean (SD) 26.46 (4.99)  25.13 (4.47)  25.66 (5.21)  26.46 (4.83)  24.56 (4.16)  24.87 (4.20)  25.46 (4.23)  0.000
b 
Diabetes, n (%) 3 (5.45)  57 (4.17)  11 (6.43)  9 (4.37)  9 (2.49)  28 (4.46)  88 (5.19)  0.293 Dyslypidemia, n (%) 20 (36.36)  406 (29.70)  54 (31.58)  60 (29.13)  104 (28.73)  188 (29.94)  563 (33.20)  0.379 Hypertension, n (%) 13 (23.64)  364 (26.63)  44 (25.73)  67 (32.52)  95 (26.24)  158 (25.16)  525 (30.96)  0.036 Inflammatory markers at baseline, Median (IQR)                     Interleukin-6 1.24 (0.35-2.64)  1.19 (0.50-3.04)  1.25 (0.63-3.37)  1.29 (0.56-3.25)  1.22 (0.52-2.73)  1.13 (0.45-3.04)  1.34 (0.60-3.36)  0.106 Tumor Necrosis Factor-α 2.52 (1.65-3.91)  2.69 (1.62-4.29)  2.54 (1.62-4.17)  2.89 (1.71-4.81)  2.72 (1.63-4.26)  2.61 (1.57-4.26)  2.87 (1.85-4.47)  0.067 High-sensitivity C-Reactive protein 1.30 (0.70-3.10)  1.00 (0.50-2.10)  0.90 (0.50-2.20)  1.10 (0.60-2.60)  1.00 (0.50-2.20)  1.00 (0.50-2.00)  1.00 (0.50-2.20)  0.030 Inflammatory markers at follow-up, Median (IQR)                     Interleukin-6 2.49 (1.25-6.10)  2.31 (0.89-7.79)  2.44 (0.73-5.54)  2.51 (0.80-8.92)  2.05 (0.85-7.27)  2.35 (0.93-8.02)  2.82 (0.98-8.83)  0.100 Tumor Necrosis Factor-α 5.35 (2.98-7.86)  4.48 (2.43-8.07)  4.52 (2.17-7.51)  4.25 (2.33-9.14)  4.56 (2.80-7.89)  4.53 (2.42-8.09)  4.72 (2.52-8.27)  0.826 High-sensitivity C-Reactive protein 1.60 (0.90-3.40)  1.10 (0.60-2.50)  1.20 (0.70-2.60)  1.40 (0.70-3.20)  1.10 (0.60-2.70)  1.10 (0.50-2.35)  1.20 (0.60-2.50)  0.018 
Abbreviations: SD = standard deviation; MDD = major depressive disorder; IQR=Interquartile range (the 25% and 75% are provided). 
Median and IQR of inflammatory markers were not logarithmically transformed (n IL-6, TNF- α = 2796, n hsCRP = 2896).  
a Chi-square Test; b Kruskal-Wallis Test.
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TABLE 2: Associations between current and remitted mood disorders at baseline and inflammatory markers at follow-up 
  Interleukin 6 [pg/ml]   Tumor Necrosis Factor-α [pg/ml]   hs C-Reactive Protein [mg/l] 
 β
a (95% CI) p-value  β
a (95% CI) p-value  β
a (95% CI) p-value 
Current diagnoses       
Bipolar Disorder  -1.29 (-3.51-0.93) 0.256  0.17 (-1.22-1.56) 0.810  -0.61 (-1.66-0.43) 0.251 
Major Depressive Disorder -0.10 (-0.33-0.14) 0.429  -0.06 (-0.21-0.09) 0.427  0.12 (0.01-0.22) 0.037 
MDD Combined Subtype -0.69 (-1.23/-0.14) 0.014  -0.27 (-0.61-0.08) 0.127  0.33 (0.07-0.59) 0.011 
MDD Atypical Subtype  -0.12 (-0.62-0.37) 0.627  0.04 (-0.27-0.35) 0.809  0.36 (0.14-0.58) 0.002 
MDD Melancholic Subtype -0.07 (-0.55-0.42) 0.785  -0.18 (-0.48-0.12) 0.247  -0.09 (-0.31-0.13) 0.406 
MDD Unspecified Subtype 0.19 (-0.19-0.56) 0.322   0.06 (-0.17-0.29) 0.622   -0.02 (-0.19-0.16) 0.855 
Remitted diagnoses                       
Bipolar Disorder  0.14 (-0.33-0.60) 0.567  0.09 (-0.20-0.38) 0.550  0.18 (-0.04-0.39) 0.111 
Major Depressive Disorder -0.07 (-0.19-0.06) 0.300  -0.00 (-0.08-0.07) 0.925  -0.03 (-0.08-0.03) 0.384 
MDD Combined Subtype -0.05 (-0.34-0.24) 0.740  0.00 (-0.18-0.19) 0.984  -0.08 (-0.22-0.05) 0.226 
MDD Atypical Subtype  -0.02 (-0.29-0.24) 0.856  -0.11 (-0.28-0.06) 0.189  -0.03 (-0.16-0.10) 0.640 
MDD Melancholic Subtype -0.19 (-0.38-0.01) 0.069  0.06 (-0.07-0.18) 0.379  0.01 (-0.08-0.10) 0.781 
MDD Unspecified Subtype 0.03 (-0.13-0.19) 0.691   -0.00 (-0.10-0.10) 0.954   -0.02 (-0.09-0.06) 0.675 
Abbreviations: β = β-estimator; CI = confidence interval; MDD = major depressive disorder. 
Models adjusted for the corresponding inflammatory marker at baseline, “No mood disorders” considered as the 
comparison group. 
ᵃ multiple regression with logarithmically transformed cytokine (n = 2796) or hsCRP concentrations (n = 2896). 
Statistically significant results are in bold. 
p-values are in italic. 
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TABLE 3: Adjusted associations between current and remitted mood disorders at baseline and inflammatory markers at follow-up 
  Interleukin 6 [pg/ml]   Tumor Necrosis Factor-α [pg/ml]   hs C-Reactive Protein [mg/l] 
  βa (95% CI) p-value  β
a (95% CI) p-value  β
a (95% CI) p-value 
Current diagnoses       
Bipolar Disorder  -- -- --  -- -- --  -- -- -- 
MDD Combined Subtype -0.74 (-1.30\-0.18) 0.010  -0.26 (-0.61-0.09) 0.141  0.29 (0.03-0.55) 0.026 
MDD Atypical Subtype  -0.17 (-0.67-0.34) 0.521  0.04 (-0.28-0.35) 0.814  0.32 (0.10-0.55) 0.005 
MDD Melancholic Subtype -0.14 (-0.64-0.35) 0.573  -0.13 (-0.44-0.18) 0.412  -0.10 (-0.33-0.12) 0.362 
MDD Unspecified Subtype 0.14 (-0.25-0.52) 0.478   0.08 (-0.16-0.32) 0.521   -0.01 (-0.19-0.16) 0.889 
Remitted diagnoses                       
Bipolar Disorder  0.04 (-0.46-0.55) 0.872  -0.01 (-0.32-0.30) 0.954 0.13 (-0.10-0.37) 0.261 
MDD Combined Subtype -0.13 (-0.44-0.18) 0.415  -0.01 (-0.20-0.18) 0.916 -0.09 (-0.23-0.05) 0.202 
MDD Atypical Subtype  -0.10 (-0.38-0.19) 0.499  -0.10 (-0.28-0.08) 0.268 -0.04 (-0.17-0.09) 0.552 
MDD Melancholic Subtype -0.23 (-0.45\-0.02) 0.036  0.06 (-0.07-0.20) 0.372 0.03 (-0.07-0.13) 0.517 
MDD Unspecified Subtype -0.04 (-0.21-0.13) 0.649   0.00 (-0.10-0.11) 0.970   0.00 (-0.08-0.08) 0.983 
Abbreviations: β = β-estimator; CI = confidence interval; MDD = major depressive disorder. 
Models adjusted for the corresponding inflammatory marker at baseline, length of follow-up, socio-demographic variables (age, gender, socio-economic status, ethnicity and 
marital status), medications, comorbid mental disorders (anxiety and substance use disorders), behavioral cardiovascular risk factors (physical activity and smoking status) and 
physical cardiovascular risk factors (BMI, diabetes, hypertension and dyslipidemia) at baseline. “No mood disorders” considered as the comparison group. 
Associations between inflammatory markers and a current diagnosis of bipolar disorder could not be assessed due to small sample size. 
ᵃ Multiple regression with logarithmically transformed cytokine (n = 2797) or hsCRP concentrations (n = 2896). 
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TABLE 4: Associations between inflammatory markers at baseline and mood disorders at follow-up (n=2580) 
Levels of 
Inflammatory 
marker at 
baseline 
Bipolar disorder   MDD   MDD Combined Subtype   MDD Atypical Subtype   
MDD Melancholic 
Subtype   
MDD Unspecified 
Subtype 
n = 13  n = 608  n = 67  n = 129  n = 155  n = 257 
OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value   OR (95% CI) p-value 
Model 1                                               
IL-6 [pg/ml] 0.68 (0.37-1.25) 0.215  0.96 (0.88-1.06) 0.436  0.95 (0.74-1.22) 0.703  0.87 (0.73-1.05) 0.153  1.04 (0.88-1.22) 0.674  0.96 (0.84-1.09) 0.497 
TNF-α [pg/ml] 0.75 (0.40-1.41) 0.372  0.86 (0.78-0.95) 0.002  1.02 (0.80-1.30) 0.889  0.83 (0.69-1.00) 0.046  0.90 (0.76-1.06) 0.214  0.86 (0.75-0.98) 0.023 
hsCRP [mg/l] 0.98 (0.56-1.69) 0.929   0.93 (0.85-1.03) 0.148   1.03 (0.81-1.32) 0.786   0.98 (0.82-1.18) 0.849   0.87 (0.74-1.03) 0.101   0.94 (0.82-1.07) 0.312 
Model 2                                               
IL-6 [pg/ml] 0.74 (0.35-1.56) 0.431  1.01 (0.91-1.12) 0.857  0.94 (0.72-1.23) 0.642  0.88 (0.72-1.08) 0.221  1.08 (0.91-1.28) 0.386  1.02 (0.88-1.17) 0.826 
TNF-α [pg/ml] 0.75 (0.34-1.63) 0.467  0.85 (0.77-0.95) 0.003  1.05 (0.81-1.36) 0.713  0.85 (0.69-1.04) 0.117  0.88 (0.74-1.05) 0.162  0.86 (0.74-0.99) 0.034 
hsCRP [mg/l] 1.10 (0.57-2.12) 0.772   0.90 (0.81-1.00) 0.054   1.05 (0.80-1.38) 0.704   0.88 (0.72-1.08) 0.219   0.94 (0.79-1.14) 0.544   0.90 (0.78-1.04) 0.143 
Abbreviations: IL-6 = Interleukin-6; TNF-α = Tumor Necrosis Factor-α; hsCRP = high sensitivity C-Reactive Protein; OR = odds ratio; CI = confidence interval; MDD = major depressive 
disorder. 
Model 1: adjusted for the corresponding mental disorder at baseline. 
Model 2: adjusted for the corresponding mental disorder at baseline, length of follow-up, socio-demographic variables (gender, age, socio-economic status, ethnicity and marital 
status), medications, health-related behaviors (former smoker, current smoker and physical inactivity), and physical cardiovascular risk factors (body mass index, diabetes, 
dyslipidemia and hypertension) at baseline. 
 
